<DOC>
	<DOCNO>NCT00668122</DOCNO>
	<brief_summary>To assess compare efficacy safety ciprofloxacin extended-release ( CIPRO XR ) tablet 1000 mg PO once-daily ( OD ) versus ciprofloxacin immediate-release ( CIPRO IR ) tablet 500 mg PO twice-daily ( BID ) 7-14 day patient complicate and/or nosocomial urinary tract infection ( cUTI ) .</brief_summary>
	<brief_title>Efficacy Safety CIPRO XR Versus CIPRO IR Patients With Complicated Urinary Tract Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>The primary diagnosis clinical trial cUTI men nonpregnant woman 18 year age . Other main inclusion criterion : One clinical symptom sign low UTI : fever ( &gt; 38°C , orally ) , chill , frequency micturition , dysuria , urge sensation . One follow underlying condition suggestive cUTI : Indwelling urinary catheter . 100 mL residual urine voiding . Neurogenic bladder . Obstructive uropathy due lithiasis , tumor fibrosis . Acute urinary retention men . Diagnosis pyelonephritis support clinical signs/symptoms fever ( &gt; 38°C orally ) , chill flank pain ( 3 signs/symptoms must present ) . Have history allergy quinolones Are unable take oral medication Have intractable infection require &gt; 14 day therapy Have requirement concomitant administration sucralfate divalent trivalent cation iron antacid contain magnesium , aluminum calcium Have prostatitis epididymitis Have renal transplant Have ileal loop vesica urethral reflux Have significant liver kidney impairment Have history tendinopathy associate fluoroquinolones Are pregnant , nurse Have history convulsion CNS disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
</DOC>